James G Krueger Selected Research

efalizumab (Raptiva)

1/2012	Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs.
11/2008	Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.
5/2008	Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
2/2007	Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
12/2005	Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).
8/2005	Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
3/2005	Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis.
10/2004	Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
5/2002	Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James G Krueger Research Topics

Disease

156	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2022 - 01/2002
49	Inflammation (Inflammations) 01/2022 - 07/2004
43	Atopic Dermatitis (Atopic Eczema) 01/2022 - 11/2008
19	Hyperplasia 01/2022 - 04/2006
18	Skin Diseases (Skin Disease) 01/2022 - 01/2002
13	Neoplasms (Cancer) 07/2020 - 04/2006
12	Alopecia Areata 10/2022 - 01/2015
10	Hidradenitis Suppurativa 01/2022 - 01/2018
10	Melanoma (Melanoma, Malignant) 11/2020 - 12/2013
8	Atherosclerosis 10/2021 - 01/2012
6	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 10/2004
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 07/2020 - 04/2006
5	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 07/2010
5	Psoriatic Arthritis 01/2019 - 01/2011
4	Infections 01/2018 - 12/2005
4	Hypersensitivity (Allergy) 10/2017 - 10/2014
3	Alopecia (Baldness) 10/2022 - 10/2021
3	Erythema 01/2021 - 03/2012
3	Pruritus (Itching) 10/2019 - 01/2019
3	Ichthyosis (Xeroderma) 01/2019 - 01/2017
3	Neoplasm Metastasis (Metastasis) 10/2016 - 01/2015
3	Contact Dermatitis (Eczema, Contact) 03/2015 - 02/2013
3	Rheumatoid Arthritis 03/2010 - 05/2007
2	Eczema 10/2021 - 01/2016
2	Dermatitis 09/2021 - 10/2019
2	Necrosis 01/2020 - 03/2013
2	Keloid 01/2020 - 01/2017
2	Parakeratosis 01/2020 - 11/2015
2	Vitiligo 01/2019 - 04/2011

Drug/Important Bio-Agent (IBA)

60	CytokinesIBA 01/2022 - 01/2004
46	Interleukin-17 (Interleukin 17)IBA 11/2021 - 05/2008
28	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2006
26	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2007
22	Interleukin-23 (Interleukin 23)IBA 09/2021 - 01/2004
20	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 07/2004
14	InterleukinsIBA 01/2022 - 01/2004
12	Messenger RNA (mRNA)IBA 01/2021 - 02/2003
12	Interleukin-22 (IL-22)IBA 01/2020 - 11/2008
12	Interleukin-12 (IL 12)IBA 01/2019 - 02/2003
9	Keratin-16 (Keratin 16)IBA 01/2022 - 05/2002
9	Biological ProductsIBA 01/2021 - 01/2002
9	Etanercept (Enbrel)FDA Link 01/2020 - 08/2005
9	ChemokinesIBA 01/2017 - 07/2004
9	efalizumab (Raptiva)FDA Link 01/2012 - 05/2002
8	Ustekinumab (CNTO 1275)FDA Link 01/2022 - 08/2011
8	brodalumabIBA 01/2022 - 03/2012
8	RNA (Ribonucleic Acid)IBA 11/2021 - 01/2012
6	dupilumabIBA 10/2022 - 12/2014
6	Monoclonal AntibodiesIBA 01/2022 - 08/2011
6	LipidsIBA 01/2021 - 01/2017
6	InterferonsIBA 01/2021 - 01/2004
6	Filaggrin ProteinsIBA 01/2021 - 01/2017
6	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2021 - 12/2005
6	AntibodiesIBA 01/2020 - 03/2008
6	Tumor Necrosis Factor InhibitorsIBA 01/2020 - 05/2007
6	tofacitinibIBA 01/2020 - 09/2009
5	secukinumabIBA 05/2022 - 05/2016
5	Interleukin-6 (Interleukin 6)IBA 01/2022 - 01/2018
5	Janus KinasesIBA 01/2022 - 10/2019
5	ixekizumabIBA 01/2018 - 07/2012
5	LigandsIBA 04/2017 - 05/2007
5	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2017 - 02/2008
5	diphenylcyclopropenoneIBA 10/2016 - 10/2014
5	Alefacept (Amevive)FDA Link 02/2010 - 02/2005
4	Blood Proteins (Serum Proteins)IBA 01/2022 - 01/2014
4	Interleukin-10 (Interleukin 10)IBA 11/2021 - 10/2007
4	Interleukin-13IBA 01/2021 - 10/2017
4	loricrinIBA 01/2021 - 01/2019
4	Adalimumab (Humira)FDA Link 05/2020 - 08/2015
4	Interleukin-8 (Interleukin 8)IBA 01/2020 - 08/2005
4	Pharmaceutical PreparationsIBA 01/2020 - 03/2002
4	Immunoglobulin E (IgE)IBA 01/2019 - 11/2015
4	risankizumabIBA 01/2019 - 07/2015
4	apremilastIBA 08/2018 - 08/2013
4	AntigensIBA 01/2018 - 09/2011
3	SaltsIBA 10/2022 - 10/2021
3	Janus Kinase InhibitorsIBA 01/2022 - 05/2016
3	Lipocalin-2IBA 01/2022 - 11/2008
3	EnzymesIBA 11/2021 - 01/2016
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 03/2002
3	Interleukin-17 ReceptorsIBA 01/2020 - 06/2011
3	Interleukin-4 (Interleukin 4)IBA 01/2019 - 10/2007
3	6-sulfo sialyl Lewis XIBA 01/2019 - 10/2015
3	HaptensIBA 12/2015 - 10/2014
2	ProteomeIBA 01/2022 - 01/2021
2	deucravacitinibIBA 01/2022 - 01/2022
2	TYK2 Kinase (Tyrosine Kinase 2)IBA 01/2022 - 01/2022
2	Imiquimod (Aldara)FDA LinkGeneric 09/2021 - 10/2019
2	SteroidsIBA 01/2021 - 01/2016
2	Immunomodulating AgentsIBA 10/2020 - 07/2010
2	p38 Mitogen-Activated Protein KinasesIBA 10/2019 - 01/2018
2	DefensinsIBA 01/2019 - 04/2006
2	fezakinumabIBA 01/2019 - 01/2018
2	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 01/2019 - 01/2019
2	kynureninaseIBA 01/2019 - 01/2016
2	NF-kappa B (NF-kB)IBA 01/2019 - 03/2010

Therapy/Procedure

40	Therapeutics 01/2022 - 02/2003
5	Biological Therapy 01/2019 - 08/2005
5	Lasers (Laser) 03/2015 - 01/2011
3	Aftercare (After-Treatment) 10/2022 - 11/2020